22057 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Hudis
    Hudis
  4. Kris
    Kris
  5. Saltz
    Saltz
  6. Offit
    Offit
  7. O'Reilly
    O'Reilly
  8. Solit
    Solit
  9. Robson
    Robson
  10. Drilon
    Drilon

Groups

  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)
  7. Breast Medicine Service (4103)
  8. Surgery (4019)
  9. Department of Pathology and Laboratory Medicine (3422)
  10. Thoracic Oncology (3351)
  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune checkpoint combos in metastatic castration-resistant prostate cancer: Where are we going, what are we doing, and why?
    Editorial

    Slovin, S. F.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with stereotactic radiosurgery
    Journal Article

    Gaeta, B.; Eichholz, J. E.; Walch, H.; Ilica, A. T.; Boe, L.; Kratochvil, L.; Yu, Y.; Gomez, D. R.; Imber, B. S.; Li, B. T.; more...
    International Journal of Radiation Oncology, Biology, Physics (2025)

    Fulltext@MSK | Save
  • Localized and diffuse tenosynovial giant cell tumor: Real-world results from a patient observational registry
    Journal Article

    Stern, S.; McKenzie, P. F.; Bernthal, N.; O’Neill, S.; Palmerini, E.; Randall, R. L.; Tap, W.; Scharschmidt, T.; Rothschild, S.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Enfortumab vedotin and pembrolizumab: Redefining the standard of care for previously untreated advanced urothelial cancer
    Review

    Sternschuss, M.; Rosenberg, J. E.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Tumor immunophenotypic correlates in patients aged 80 years or older with non-small cell lung cancer and outcomes to first-line pembrolizumab in PD-L1 high (≥50%) patients
    Journal Article

    Barrichello, A. P. C.; Elkrief, A.; Ricciuti, B.; Ganta, T.; Marron, T. U.; Wang, X.; Lotter, W.; Lindsay, J.; Santo, V.; Cortellini, A.; more...
    Clinical Lung Cancer (2025)

    Fulltext@MSK | Save
  • A phase two, single-arm, open-label study with dostarlimab monotherapy in participants with untreated stage II/III dMMR/MSI-H Locally advanced rectal cancer (AZUR-1)
    Journal Article

    Cercek, A.; Bachet, J. B.; Capdevila, J.; Starling, N.; Chen, E.; Salvatore, L.; Bando, H.; O'Donnell, S.; Harfst, L.; Szijgyarto, Z.; more...
    Clinical Colorectal Cancer (2025)

    Fulltext@MSK | Save
  • Optimizing postneoadjuvant treatment of residual breast cancer with adjuvant bevacizumab alone, with metronomic or standard-dose chemotherapy: A combined analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE clinical trials
    Journal Article

    Trapani, D.; Jin, Q.; Miller, K. D.; Rugo, H. S.; Reeder-Hayes, K. E.; Traina, T.; Abdou, Y.; Falkson, C.; Abramson, V.; Ligibel, J.; more...
    Clinical Breast Cancer (2025)

    Fulltext@MSK | Save
  • Minimum requirements to safely establish and sustain new hepatic arterial infusion pump programs: An international expert perspective
    Review

    Merkow, R. P.; Cavnar, M. J.; Gleisner, A. L.; Mayo, S. C.; Gholami, S.; Karanicolas, P. J.; Koerkamp, B. G.; Homs, M. Y. V.; Connell, L. C.; Cercek, A.; more...
    Annals of Surgical Oncology (2025)

    Fulltext@MSK | Save
  • Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
    Journal Article

    Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
    Guidelines

    Westphalen, C. B.; Boscolo Bielo, L.; Aftimos, P.; Beltran, H.; Benary, M.; Chakravarty, D.; Collienne, M.; Dienstmann, R.; El Helali, A.; Gainor, J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save